69791人已查看 《Oxidative Medicine and Cellular Longevity》 期刊2024最新IF预测值
预警说明查看说明
时间
预警情况
预警提示
2023年3月20日剔除出SCIE目录
2024年02月发布的2024版
不在预警名单中
2023年01月发布的2023版
不在预警名单中
2021年12月发布的2021版
不在预警名单中
2020年12月发布的2020版
不在预警名单中
2025年预警名单预测
无异常数据 期刊预警概率很低
结果仅供参考
*来源:中科院《 国际期刊预警名单》
中科院分区查看说明
版本
大类学科
小类学科
Top期刊
综述期刊
2022年12月最新升级版
生物学2区
CELL BIOLOGY
细胞生物学
2区
否
否
2021年12月升级版
生物2区
CELL BIOLOGY
细胞生物学
3区
否
否
2021年12月升级版
生物学2区
CELL BIOLOGY
细胞生物学
3区
否
否
2020年12月升级版
生物学2区
CELL BIOLOGY
细胞生物学
3区
否
否
JCR分区
WOS分区等级:Q0区
版本
按学科
分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of
Science)为每个学科内的期刊按照IF数值排序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2022-2023年最新版)
暂无数据
暂无数据
测一测你投这本期刊的成功率
【官方推荐】国内首个期刊投稿预测系统,多维度分析投稿成功率,助你精准决策
12502
人已预测
期刊介绍
Oxidative Medicine and Cellular Longevity is a unique peer-reviewed, Open Access journal that publishes original research and review articles dealing with the cellular and molecular mechanisms of oxidative stress in the nervous system and related organ systems in relation to aging, immune function, vascular biology, metabolism, cellular survival and cellular longevity. Oxidative stress impacts almost all acute and chronic progressive disorders and on a cellular basis is intimately linked to aging, cardiovascular disease, cancer, immune function, metabolism and neurodegeneration. The journal fills a significant void in today’s scientific literature and serves as an international forum for the scientific community worldwide to translate pioneering “bench to bedside” research into clinical strategies.
Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis
来源期刊:Oxidative Medicine and Cellular Longevity
DOI:10.1155/2019/5080843
The Bioprotective Effects of Polyphenols on Metabolic Syndrome against Oxidative Stress: Evidences and Perspectives
来源期刊:Oxidative Medicine and Cellular Longevity
DOI:10.1155/2019/6713194
Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF
来源期刊:Oxidative Medicine and Cellular Longevity
DOI:10.1155/2019/8148510
Curcumin Inhibits the PERK-eIF2α-CHOP Pathway through Promoting SIRT1 Expression in Oxidative Stress-induced Rat Chondrocytes and Ameliorates Osteoarthritis Progression in a Rat Model
来源期刊:Oxidative Medicine and Cellular Longevity
DOI:10.1155/2019/8574386
Nrf2/Keap1/ARE Signaling Mediated an Antioxidative Protection of Human Placental Mesenchymal Stem Cells of Fetal Origin in Alveolar Epithelial Cells
来源期刊:Oxidative Medicine and Cellular Longevity
DOI:10.1155/2019/2654910
已经到底了~
测一测你投这本期刊的成功率
【官方推荐】国内首个期刊投稿预测系统,多维度分析投稿成功率,助你精准决策
12502
人已预测
鹿粉147103
2022-11-08 18:19:53
ae invited持续三个月然后发邮件说找不到学术编辑给我撤稿了
鹿粉196691
2022-11-08 18:19:53
请问有知道该刊校稿过程中出现问题怎么和编辑部联系吗?
编辑发信让校稿,按照说明所有作者登陆各自的校稿账号后都能看到这篇需要校稿的文章,唯独通讯作者没有,通讯作者校稿系统显示的是there are no active galley proofs。其他作者只能预览不能校对修改,给编辑部反应该问题,但一直没有解决,但编辑部还一直催我们校稿,都催我们三次了,我们也回复他们三次该问题的存在。有知道怎么办的吗,谢谢!!!
哪位大佬知道这啥情况?“during our post acceptance checks we have unfortunately identified a potential issue with the handing of your paper during the peer review process. In order to progress your paper, therefore, we have invited another member of the editorial board to reasess you manuscript and its peer review thus far. The new editor will either invite additional reviewers, if necessary, or you will be notified of a decision as soon as possible.”修回去N天,Pending approval后好几天,突然收到这个邮件,此时状态又跳回under review了,这是啥情况呀?
大佬们,1月底投的专刊,3月底给大修,遇到疫情,6月初修回,到现在还是Under Review。一个半月发邮件,回复 Many thanks for your email. Please be informed that we are inviting Reviewers to review the manuscript and hopefully we shall get back to you soon with a positive response. 是不是要重新邀请审稿人开始审稿。可是专刊栏目都关了啊。有没有大佬有经验的,特别着急。求分享经验。
各位亲们,咨询一下,文章二审修回后两个月没消息,我发了邮件问了一下,编辑回复是Many thanks for your email and please be informed that we are inviting Reviewers to review the manuscript. As soon as we receive the report we shall get back to you soon with a positive response. 这意思是原来的审稿人不审了,在重新找审稿人吗?